GUWAHATI: Bharat Biotech’s COVID19 vaccine, COVAXIN has demonstrated 78 percent efficacy against the virus in its Phase III trials, reported agencies. Bharat Biotech has submitted data from Phase III clinical trials of COVAXIN to the Drugs Controller General of India.
The Phase 3 study had enrolled 25,800 participants between 18-98 years of age, including 10% over the age of 60, with analysis conducted 14 days post 2nd dose.
COVAXIN was developed with seed strains received from the National Institute of Virology, and the phase 3 clinical trial was co-funded by the Indian Council of Medical Research, making it a true public, private partnership towards public health.
COVAXIN was approved and introduced initially through Emergency Use Authorization under the clinical trial mode, resulting in robust safety data in real-life conditions.
